ERWINASE
Study on Investigational Treatment for Allergic Reactions in Blood Cancer Patients
Brief description of study.
The purpose of this study is to provide a way to treat subjects receiving Acute Lymphoblastic Leukemia (ALL) treatment and who are allergic to the commonly used drugs Elspar
Detailed description of study
The purpose of this study is to provide a way to treat subjects receiving Acute Lymphoblastic Leukemia (ALL) treatment and who are allergic to the commonly used drugs Elspar
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Acute Lymphoblastic Leukemia
-
Age: 100 years or below
-
Gender: All
This study investigates a treatment for patients who are receiving therapy for Acute Lymphoblastic Leukemia (ALL) and are allergic to certain commonly used drugs. Acute Lymphoblastic Leukemia is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature white blood cells.
Participants in the study will be assigned to different study arms to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
- Who can participate: Individuals aged 18 and older with Acute Lymphoblastic Leukemia who are allergic to standard drugs used in treatment may qualify for this study.
- Study details: Participants will be assigned to different study arms to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
